Why the study?
Is the decline in mortality following NSTEMI associated with lower baseline risk, increased use of pharmacological therapies, or the use of an invasive coronary strategy?
Population
389,057 patients with NSTEMI in 247 hospitals in England and Wales, median age 72.7 years, 63.1% men.
Comparison
Use of an invasive coronary strategy and… vs Earlier time periods and non-invasive management.
Design
Cohort
Follow-up
180 days postdischarge
Authors
Loading...
Invasive strategy use was associated with NSTEMI mortality decline; hypothesis-generating, leaves causal effect and practice change open.
Is the decline in mortality following NSTEMI associated with lower baseline risk, increased use of pharmacological therapies, or the use of an invasive coronary strategy?
Improvements in 180-day mortality following NSTEMI between 2003 and 2013 were significantly associated with the increased use of an invasive coronary strategy, rather than solely a decline in baseline clinical risk or increased use of pharmacological therapies.
Hall et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: